Key takeaways:

The meta-analysis included more than 50 clinical trials and observational studies.

Subjects included women who used estrogen, estrogen and progestin, and estrogen with a selective estrogen receptor modulator.

BALTIMORE — Risks for developing Alzheimer’s disease can increase or decrease depending on when women begin hormone replacement therapy, according to data presented at the American Neurological Association Annual Meeting 2025.

The meta-analysis comprised more than 50 clinical trials and observational studies, FNU Vaibhav, MBBS, a student at Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences in Rohtak, India, said during the presentation.

Data derived from Vaibhav FNU, et al. Timing-dependent effects of estrogen therapy on Alzheimer’s disease

See Full Page